|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the School of Social Administration (Drs. Widerman and Millner), Temple University, Philadelphia, PA; and Hahnemann School of Medicine (Drs. Sexauer and Fiel), Philadelphia, PA.
Correspondence to: Eileen Widerman, PhD, School of Social Administration, RA 501 00400, Temple University, Philadelphia, PA 19122; e-mail: ewiderma{at}astro.ocis.temple.edu
| Abstract |
|---|
|
|
|---|
Design:
The 1996 Cystic Fibrosis Foundation (CFF) Patient Registry data were
analyzed to test for associations between age at diagnosis and selected
variables. All cases involved individuals
18 years who were
represented in the CFF Patient Registry for 1996. Patients were
assigned to one of two groups: those diagnosed with CF after age 18
years (n = 786) and those diagnosed before 18 years
(n = 6,641).
Results: In 1996, the incidence of late diagnosis was 7.8%, and the prevalence was 10.9%. The mean age of late diagnosis was 27 years. Respiratory symptoms most frequently led to late diagnosis. Patients receiving a late CF diagnosis were less likely to have alleles for Delta F508. There was no correlation between age at diagnosis and percent predicted FEV1, although patients in the late-diagnosis group were an average of 10 years older than those in the early-diagnosis group. Late diagnosis was associated with fewer complications, fewer hospitalizations, less oxygen use, fewer courses of home IV treatment, and less enzyme use. Women were most often diagnosed late. Men displayed more diversity in conditions leading to diagnosis. Psychosocially, those patients receiving late diagnoses were more likely to be college graduates, married, and employed full time. For those adults who died in 1996, there was a positive association between their age at diagnosis and age at death.
Conclusion: Those patients diagnosed with CF as adults differ, both medically and psychosocially, from those diagnosed at a younger age; these differences have implications for diagnosis, treatment, and education.
Key Words: cystic fibrosis cystic fibrosis adult cystic fibrosis diagnosis cystic fibrosis late diagnosis
| Introduction |
|---|
|
|
|---|
| Incidence and Prevalence of Late Diagnosis in CF |
|---|
|
|
|---|
18 years in 1997, 11.5% had received their
diagnoses as adults.2
Just 3 years earlier, new diagnoses
in those patients > 18 years of age represented just 5.8% of the
total of new diagnoses.3 | History and Background |
|---|
|
|
|---|
| Relevant Literature |
|---|
|
|
|---|
Other researchers have studied those patients who have received a diagnosis of CF as adolescents and/or adults, both in the United States and in Europe.12 13 14 These studies, most of which are unpublished, have involved small samples but indicate, like the study of Widerman,11 that receiving a diagnosis of CF after childhood may result in a range of reactions and may necessitate significant changes in lifestyle.
| Purpose |
|---|
|
|
|---|
The purpose of this study was to analyze the 1996 CFF Annual Registry data for the following reasons: (1) to determine how, if at all, men and women receiving a diagnosis of CF after age 18 differed from adults receiving a diagnosis before age 18 on selected CF-related and demographic characteristics that year; and (2) to explore the extent to which identified differences were associated with gender.
| Materials and Methods |
|---|
|
|
|---|
The data were transferred to a mainframe computer for analysis using
appropriate software (SAS; SAS Institute; Cary, NC), selecting as cases
those involving patients aged
18 years (n = 7,427). These
patients then were assigned to one of two groups: group ED (early
diagnosis), comprising adults who had received diagnoses of CF at
17 years (n = 6,641); or group AD (adult diagnosis), comprising
adults who received diagnoses of CF at
18 years (n = 786). These
two groups then were compared. Variables created by the CFF were
utilized where possible, and new variables were created as necessary to
address the issues of interest in the study.
2
analyses, t tests, and Pearson correlation were employed. In
most cases, data were further analyzed by gender, in that gender has
been shown to be associated with longevity in CF.15
| Results |
|---|
|
|
|---|
18 years of age in the United States
(data available for 7,427), representing 35.6% of the CFF Registry
adult cases. Of those, 813 individuals (10.9%) had received diagnoses
at
18 years of age (data available for 786). Among individuals
receiving new diagnoses that year, 71 (7.8%) received diagnoses at age
18 years of age.
Sociodemographic Description
There were significant relationships between age at diagnosis and
the following sociodemographic variables: current age, race, gender,
educational attainment, marital status, and employment status.
In 1996, patients in group AD were older (mean, 36.83; SD, 9.58;) than
those in group ED (mean, 26.34; SD, 7.01; p < 0.00001). Although the
patients in group AD were predominantly white (97.51%),
2 testing revealed a significant
relationship (p = 0.011) between race and age at diagnosis for
Asians/Pacific Islanders (late diagnosis, 31.25%) compared to blacks
(late diagnosis, 7.41%) and whites (late diagnosis, 10.68%).
Over one half of adults with CF in 1996 were men, yet women were more likely to receive a late diagnosis, as illustrated in Table 1 .
|
In 1996, most adults with CF had medical insurance coverage (97.50%). Those in group ED were more likely to have state-based coverage than those in group AD (31.21% vs 24.55%, respectively; p = 0.0001), which would be expected given the eligibility requirements of these programs. Among all adults with CF, 17.72% were members of a health maintenance organization.
Diagnosis
For all adults included in the 1996 CFF Registry, the mean age at
diagnosis was 5.51 years. The mean age at diagnosis for group AD was
27.36 years for women and 27.20 for men (difference not
significant). Again,
2 analysis
revealed that women were significantly more likely to be diagnosed late
than men (p = 0.001).
There were significant associations between age at diagnosis and the condition suggesting the diagnosis, as illustrated in Table 2 .
|
2 testing showed that a
significantly larger proportion of those patients in group AD received
diagnoses based on respiratory symptoms (p = 0.001). Those
patients in group ED demonstrated more diversity in the condition
suggesting the diagnosis, most likely due to the number of conditions
suggestive of CF that appear in infancy and childhood. Older patients
more frequently received diagnoses due to the presence of nasal polyps
and the results of genotyping. Although it seems probable that those
patients with family histories of CF might receive diagnoses earlier,
there was no difference between the groups for this variable. The
finding that the category "other conditions" more often led to late
diagnosis lends support to those who say that delayed confirmation of
CF may be due to atypical presentations. Interestingly, gender differences in conditions leading to diagnosis were found only among patients in group AD, as examined in Table 3 . There were no gender differences related to conditions leading to diagnosis for group ED.
|
2 analysis indicated that men were
significantly more likely to receive diagnoses as a consequence of
genotyping (p = 0.013), perhaps suggested by infertility testing. The
number of men diagnosed late as a result of infertility testing could
not be determined from the CFF 1996 data set because this variable was
not assessed at that time. | CF Characteristics/Health Status |
|---|
|
|
|---|
|
Lung Function: The percent predicted of FVC and FEV1 scores was submitted to analysis to identify differences, if any, between groups AD and ED. Results appear in Table 5 .
|
To further investigate the relationship between
FEV1 scores and age at diagnosis, additional
t tests were run. Specific age groupings within groups ED
and AD were compared for the FEV1 variable.
Results showed that, for similar age groups, group AD consistently, and
significantly, displayed higher FEV1 scores.
The ages investigated included ages 25 through 27 years
(p = 0.0007), 30 through 32 years (p = 0.0044), 35 through 37 years
(p = 0.0130), and
38 years (p = 0.0334).
For all adults with CF, there were significant differences in
FEV1 lung function by gender. Using the
FEV1 categories of the CFF for illness severity
(normal, mild, moderate, and severe),
2
analyses revealed that women were more highly represented than men in
the moderate category (40.72% vs 33.80%, respectively) and the mild
category (24.76% vs 15.33%, respectively). For both diagnosis groups,
> 60% of those patients in the severe category were men. Similar
findings related to gender were found using FVC categories of illness
severity. Among those in group AD, more women appeared in the mild
category (p = 0.01) and the normal category (p = 0.02). The
opposite was found for those patients who received diagnoses at < 18
years of age.
Culture Results: There were a number of significant associations between age at diagnosis and culture results, as illustrated in Table 6 .
|
There were no significant associations between gender and culture results within group AD.
Complications:
2 testing established that a
slightly higher, and significant, percentage of those patients in group
AD than those in group ED experienced no complications during 1996
(75.83% vs 70.62%, respectively; p = 0.002). Complications that
were significantly more prevalent in group ED included cirrhosis with
portal hypertension (p = 0.020), diabetes (p = 0.001), and liver
disease requiring consultation (p = 0.020). Pancreatitis was the only
complication significantly more prevalent in group AD (p = 0.001).
These findings may be related to the identified differences in genotype
between the two groups. Research has shown that liver disease appears
to be related to pancreatic insufficiency, and pancreatitis has been
associated with mutations in the CFTR
gene.16
17
The actual number of those patients receiving diagnoses late who were treated for complications was quite low, with percentages ranging from 0.13% for gallbladder disease to 5.73% for diabetes.
National Center for Health Statistics Percentages for
Height and Weight:
2 tests revealed that, using
National Center for Health Statistics (NCHS) standards, those patients
in group AD were significantly taller (p = 0.001) and heavier
(p = 0.001) than those in group ED. Within group AD, 51.59% of
patients were at
24% of the NCHS standard weight (compared to
67.33% of those receiving a diagnosis in group ED); 28.23% were at
24% of the NCHS standard height (compared to 45.03% of those in
group ED).
Enzyme Supplement Use: Table 7 shows the significant differences in reported use of enzymes for adults with CF by age at diagnosis.
|
2 analysis. There
was, for both groups, a significant positive association between enzyme
use and the presence of one or two alleles for Delta F508
(p = 0.001). Of those patients in group AD not taking enzymes, only
1.32% were heterozygous for Delta F508. Other CF Care Variables: Patients in group AD had fewer hospitalizations (p = 0.0001) in 1996 than those in group ED. Those patients in group AD who were hospitalized had a mean duration hospital stay that was a week less than those in group ED (p = 0.0004). Patients in group AD also had fewer office visits (p = 0.0025) and fewer mean days of IV treatment (p = 0.037) than did those in group ED during 1996. There were no significant differences between groups ED and AD for oxygen use, supplemental feeding, or transplantation.
Longevity
Among the 391 reported deaths across all age groups in 1996, there
was a significant positive correlation between age at diagnosis and age
at death (r = 0.57; p = 0.0001). Twenty-four of the 283
adults who died in 1996 were members of group AD, and there was also a
positive, significant relationship for this group between age at
diagnosis and age at death (r = 0.60; p = 0.0001). The
adult death rate was 3.81% that year. For patients in group AD, the
death rate was 3.05%, and for those in group ED it was 3.90%.
For all those patients with CF, the mean age at death for 1996 was 28.74. The mean age at death for those within group ED was 27.53 years (SD, 7.48 years); the mean age for those within group AD was 41.88 years (SD, 9.76 years) (p = 0.0001). There was no significant gender difference in mean age at death for those patients in group AD (men, 41.85 years; women, 41.90 years).
Cause of Death: Regardless of age at diagnosis, respiratory conditions were the primary cause of death in adulthood for approximately 75% of those who died in 1996, followed by deaths related to transplantation (approximately 15%). There were no significant differences between groups ED and AD related to cause of death, and there were no significant gender differences within the groups.
| Discussion |
|---|
|
|
|---|
Similar to the findings of Lester et al,18 there was a strong association between genotype and age-at-diagnosis in this study. It is certainly arguable that the less common mutations more often carried by those patients receiving diagnoses late could be responsible for the greater variance in conditions leading to diagnosis and the overall better indexes of health (ie, hospitalizations, office visits, complications experiences, lung function, etc) found among those patients in group AD in this study. Research is suggesting genetic links for nontuberculous mycobacteria and pancreatitis.17 19 However, as researchers caution, relationships between the CFTR genotype and clinical manifestations of CF are multiple and complex.20
Gender differences, both within the subpopulation of those receiving diagnoses as adults as well as between those receiving diagnoses who were > 18 years of age and < 18 years of age are also worthy of note. Men with CF have long been recognized as having milder disease expression and longer life expectancy.15 This study found that this association did not hold for those receiving diagnoses late. Women were more likely to receive diagnoses late and to receive them due to respiratory conditions. Women were also more likely to evidence milder disease as categorized by the CFF using FVC and FEV1 scores. Although the CFF Registry did not assess congenital bilateral absence of the vas deferens as a reason for diagnosis, it would nevertheless be expected that a number of men in group AD would have received diagnoses via this route. Since men in whom congenital bilateral absence of the vas deferens was diagnosed present with mild, or no, lung disease, their presence in sufficient numbers should have skewed the gender comparisons of health indicators to favor men. Interestingly, this did not occur.
Since there is no evidence of gender differences in genotype, identified differences may be due to sociocultural factors. As children, boys with symptoms would be taken by parents for care; in adulthood, men are characterized as being more hesitant to seek medical care,21 perhaps explaining why women would have milder disease on diagnosis. It has been argued that physicians attribute less importance to womens complaints than to those of men,22 possibly accounting for why it takes longer for CF to be diagnosed in women, although the milder disease found among women who received late diagnoses may also be a factor.
The studys findings provide empirical support for what persons who are diagnosed late and their physicians have long hypothesized: those who receive diagnoses late are "different" from those who receive diagnoses in preadulthood.
Limitations of the Study
Although the CFF Patient Registry data yielded a comprehensive and
systematic description of adults who received diagnoses of CF after age
18, there are limitations to this study. The database did not include
individuals who received medical care outside the CFF network of
specialty centers. In 1997, Widerman11
found that 13.8%
of the 36 men and women she interviewed did not receive care from a CF
center and that an additional number only attended a CF center yearly
for assessment. Those not included in the CFF database may differ in
important sociodemographic and/or CF characteristics from those who
were. Second, the cross-sectional study design permitted associations
only. Cause-and-effect relationships could not be established, and the
results apply solely to the 1996 CFF Patient Registry participants as a
group. Third, because the data are submitted by CF centers and are
taken from medical records (which enhances validity for some
variables), their accuracy and completeness are not confirmed by
patients. Finally, the study was limited to the variables assessed by
the CFF Registry instrument.
| Conclusions and Recommendations |
|---|
|
|
|---|
Recommendations
18 years. Yet, between 1993 and 1996,
the rate of CF diagnosis in adolescents (aged 12 through 17 years)
increased from 8.8 to 13.9% as compared to 6.0 to 7.4% for those
18 years (S. Fitzsimmons, PhD; personal communication; March
24, 1998). This phenomenon is worthy of study, particularly to identify
the differences, if any, among CF and other characteristics of
adolescents and adults who received late diagnoses and patients < 12
years of age who received diagnoses of CF.
| Acknowledgements |
|---|
| Footnotes |
|---|
Received for publication November 29, 1999. Accepted for publication March 22, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
D. M. Rodman, J. M. Polis, S. L. Heltshe, M. K. Sontag, C. Chacon, R. V. Rodman, S. J. Brayshaw, G. A. Huitt, M. D. Iseman, M. T. Saavedra, et al. Late Diagnosis Defines a Unique Population of Long-term Survivors of Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 621 - 626. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Dugueperoux and M. De Braekeleer The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype Eur. Respir. J., March 1, 2005; 25(3): 468 - 473. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |